Literature DB >> 27755503

C-C Chemokine Receptor Type 2-Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants.

Jie Qin1, Yusuke Arakawa, Miwa Morita, John J Fung, Shiguang Qian, Lina Lu.   

Abstract

BACKGROUND: Islet transplantation is a promising therapeutic approach to restore the physical response to blood glucose in type 1 diabetes. Current chronic use of immunosuppressive reagents for preventing islet allograft rejection is associated with severe complications. In addition, many of the immunosuppressive drugs are diabetogenic. The induction of transplant tolerance to eliminate the dependency on immunosuppression is ideal, but remains challenging.
METHODS: Addition of hepatic stellate cells allowed generation of myeloid-derived suppressor cells (MDSC) from precursors in mouse bone marrow. Migration of MDSC was examined in an islet allograft transplant model by tracking the systemic administered MDSC from CD45.1 congenic mice.
RESULTS: The generated MDSC were expressed C-C chemokine receptor type 2 (CCR2), which was enhanced by exposure to interferon-γ. A single systemic administration of MDSC markedly prolonged survival of islet allografts without requirement of immunosuppression. Tracking the administered MDSC showed that they promptly migrated to the islet graft sites, at which point they exerted potent immune suppressive activity by inhibiting CD8 T cells, enhancing regulatory T cell activity. MDSC generated from CCR2 mice failed to be mobilized and lost tolerogenic activity in vivo, but sustained suppressive activity in vitro.
CONCLUSIONS: MDSC migration was dependent on expression of CCR2, whereas CCR2 does not directly participate in immune suppression. Expression of CCR2 needs to be closely monitored for quality control purpose when MDSC are generated in vitro for immune therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27755503      PMCID: PMC5393972          DOI: 10.1097/TP.0000000000001529

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  39 in total

Review 1.  Biological agents in kidney transplantation: belatacept is entering the field.

Authors:  Hugo Wéclawiak; Nassim Kamar; Abdoulattif Ould-Mohamed; Isabelle Cardeau-Desangles; Lionel Rostaing
Journal:  Expert Opin Biol Ther       Date:  2010-10       Impact factor: 4.388

2.  Current status of clinical islet transplantation.

Authors:  Andrew R Pepper; Boris Gala-Lopez; Oliver Ziff; Am James Shapiro
Journal:  World J Transplant       Date:  2013-12-24

3.  The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells.

Authors:  Ching-Chuan Hsieh; Hong-Shiue Chou; Horng-Ren Yang; Feng Lin; Sumantha Bhatt; Jie Qin; Lianfu Wang; John J Fung; Shiguang Qian; Lina Lu
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

4.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

Review 5.  Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship.

Authors:  Ngozi R Monu; Alan B Frey
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

6.  Testicular sertoli cells protect islet beta-cells from autoimmune destruction in NOD mice by a transforming growth factor-beta1-dependent mechanism.

Authors:  W Suarez-Pinzon; G S Korbutt; R Power; J Hooton; R V Rajotte; A Rabinovitch
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

8.  Mechanistic insights into immunomodulation by hepatic stellate cells in mice: a critical role of interferon-gamma signaling.

Authors:  Horng-Ren Yang; Hong-Shuie Chou; Xiaodong Gu; Lianfu Wang; Kathleen E Brown; John J Fung; Lina Lu; Shiguang Qian
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

9.  Murine liver allograft transplantation: tolerance and donor cell chimerism.

Authors:  S Qian; A J Demetris; N Murase; A S Rao; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

Review 10.  Current advances and travails in islet transplantation.

Authors:  David M Harlan; Norma Sue Kenyon; Olle Korsgren; Bart O Roep
Journal:  Diabetes       Date:  2009-10       Impact factor: 9.461

View more
  10 in total

Review 1.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

Review 2.  Impact of infection on transplantation tolerance.

Authors:  Shuangjin Yu; Chang Su; Xunrong Luo
Journal:  Immunol Rev       Date:  2019-09-19       Impact factor: 12.988

Review 3.  Recent advances in myeloid-derived suppressor cell biology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani; Ammar Daoud
Journal:  Front Med       Date:  2020-09-02       Impact factor: 4.592

4.  Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients.

Authors:  Shinji Okano; Kareem Abu-Elmagd; Danielle D Kish; Karen Keslar; William M Baldwin; Robert L Fairchild; Masato Fujiki; Ajai Khanna; Mohammed Osman; Guilherme Costa; John Fung; Charles Miller; Hiroto Kayashima; Koji Hashimoto
Journal:  Am J Transplant       Date:  2018-04-17       Impact factor: 8.086

5.  Preliminary assessment of the feasibility of autologous myeloid-derived suppressor cell infusion in non-human primate kidney transplantation.

Authors:  Mohamed B Ezzelarab; Angelica Perez-Gutierrez; Abhinav Humar; Martin Wijkstrom; Alan F Zahorchak; Lien Lu-Casto; Yu-Chao Wang; Roger W Wiseman; Marta Minervini; Angus W Thomson
Journal:  Transpl Immunol       Date:  2019-07-19       Impact factor: 1.708

Review 6.  Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.

Authors:  Jilu Zhang; Alan Hodges; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Cell Immunol       Date:  2021-02-04       Impact factor: 4.868

Review 7.  Roles of Myeloid-Derived Suppressor Cell Subpopulations in Autoimmune Arthritis.

Authors:  Min Li; Dongwei Zhu; Tingting Wang; Xueli Xia; Jie Tian; Shengjun Wang
Journal:  Front Immunol       Date:  2018-12-04       Impact factor: 7.561

Review 8.  Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation.

Authors:  Jordi Ochando; Patricia Conde; Alberto Utrero-Rico; Estela Paz-Artal
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

Review 9.  Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation.

Authors:  Nathaniel Oberholtzer; Carl Atkinson; Satish N Nadig
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

10.  Rapamycin Nano-Micelle Ophthalmic Solution Reduces Corneal Allograft Rejection by Potentiating Myeloid-Derived Suppressor Cells' Function.

Authors:  Chao Wei; Yuexin Wang; Li Ma; Xin Wang; Hao Chi; Sai Zhang; Ting Liu; Zhiyuan Li; Demeng Xiang; Yanling Dong; Xianggen Wu; Weiyun Shi; Hua Gao
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.